Rich Heyman, founder and executive chairman of the board of Metacrine

Rich Hey­man-backed biotech gets out the axe as it sets course on sur­vival mis­sion

Back when Rich Hey­man and the team at Metacrine float­ed their IPO in the fall of 2020, they breezed across the fin­ish line in­to Nas­daq …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.